8-K: GoodRx Q2 2025: Profit Up, Revenue Mixed Amid Headwinds

GoodRx reports increased net income and Adjusted EBITDA for Q2 2025, driven by strong pharma manufacturer solutions revenue, despite declines in prescription transactions and subscription segments.

Summary

• Revenue for the second quarter of 2025 increased 1% year-over-year to $203.1 million.
• Net income rose to $12.8 million, up from $6.7 million in the prior year, with net income margin improving to 6.3% from 3.3%.
• Adjusted EBITDA increased to $69.4 million, up from $65.4 million, with Adjusted EBITDA Margin at 34.2%.
• Pharma manufacturer solutions revenue surged 32% year-over-year to $35.0 million, driven by organic growth and expanded market penetration.
• Prescription transactions revenue decreased 3% to $143.1 million, primarily due to a 14% decrease in Monthly Active Consumers (MACs) to 5.7 million.
• Subscription revenue declined 7% to $20.5 million, attributed to a decrease in the number of subscription plans.
• Net cash provided by operating activities was $49.6 million for the quarter, a significant increase from $9.7 million in the comparable prior-year period.
• The company repurchased 10.2 million shares of Class A common stock for $46.4 million during the quarter, with $143.0 million remaining under the share repurchase program.
• Full year 2025 revenue is projected to increase from 2024, despite an estimated $35 million to $40 million revenue loss due to the Rite Aid bankruptcy and volume reduction in an integrated savings program.
• Full year 2025 Adjusted EBITDA guidance is set between $265 million and $275 million, representing 2% to 6% growth over 2024.

Sentiment

Score: 6

Explanation: The sentiment is mixed. Positives include strong profitability (Adjusted EBITDA growth), significant cash flow from operations, successful expansion in pharma manufacturer solutions, and ongoing share repurchases. Negatives include a decline in core prescription transaction revenue and Monthly Active Consumers, a decrease in subscription revenue, and a lowered full-year revenue outlook due to external headwinds. The company is demonstrating resilience in managing profitability despite revenue challenges in its traditional segments.

Positives

• Net income increased significantly to $12.8 million from $6.7 million year-over-year.
• Adjusted EBITDA grew to $69.4 million from $65.4 million, demonstrating strong profitability.
• Adjusted EBITDA Margin improved to 34.2% from 32.6%, underscoring business model durability.
• Pharma manufacturer solutions revenue showed robust growth of 32% to $35.0 million, indicating successful strategic expansion.
• Net cash provided by operating activities increased substantially to $49.6 million from $9.7 million, reflecting improved cash generation.
• The company repurchased $46.4 million of its Class A common stock, signaling confidence and returning value to shareholders.
• Launch of a new condition subscription product for erectile dysfunction expands product offerings.

Negatives

• Prescription transactions revenue decreased 3% to $143.1 million.
• Monthly Active Consumers (MACs) decreased by 14% to 5.7 million, impacted by retail pharmacy landscape changes and store closures.
• Subscription revenue decreased 7% to $20.5 million due to a decline in subscription plans.
• Full year 2025 revenue projections include an estimated $35 million to $40 million loss due to external factors like the Rite Aid bankruptcy and volume reduction in an integrated savings program.
• Cash and cash equivalents decreased to $281.3 million as of June 30, 2025, from $448.3 million at December 31, 2024.

Risks

• Limited operating history and potential unsustainability of recent growth rates.
• Challenges in achieving broad market education and changing consumer purchasing habits.
• Difficulty in attracting, acquiring, and retaining consumers cost-effectively.
• Significant reliance on the prescription transactions offering and challenges in expanding other offerings.
• Impact of changes in medication pricing and pricing structures negotiated by industry participants.
• Inability to control the categories and types of prescriptions for which savings or discounted prices can be offered.
• Reliance on a limited number of industry participants, including pharmacy benefit managers, pharmacies, and pharma manufacturers.
• Competitive nature of the healthcare industry.
• Risks related to pandemics, epidemics, or outbreaks of infectious diseases.
• Accuracy of estimates for addressable market and other operational metrics.
• Ability to respond to changes in the market for prescription pricing and to maintain and expand the use of GoodRx codes.
• Ability to maintain positive perception of the platform or enhance the brand.
• Risks related to any failure to maintain effective internal control over financial reporting.
• Risks associated with the use of social media, emails, text messages, and other messaging channels for marketing.
• Dependence on information technology systems and those of third-party vendors, and risks of failure or significant disruptions.
• Risks related to government regulation of the internet, e-commerce, consumer data and privacy, information technology, and cybersecurity.
• Risks related to the use of AI and machine learning in the business.
• Risks related to a decrease in consumer willingness to receive correspondence or any technical, legal, or other restrictions to send such correspondence.
• Risks related to any failure to comply with applicable data protection, privacy, security, advertising, and consumer protection laws.
• Ability to utilize net operating loss carryforwards and certain other tax attributes.
• Risk of being unable to realize expected benefits from restructuring and cost reduction efforts.
• Ability to attract, develop, motivate, and retain well-qualified employees.
• Risks related to the company's acquisition strategy.
• Risks related to debt arrangements.
• Interruptions or delays in service on apps or websites or any undetected errors or design faults.
• Reliance on third-party platforms to distribute offerings, including software-as-a-service technologies.
• Systems failures or other disruptions in the operations of parties on which the company depends.
• Risks related to climate change and increasing focus on environmental sustainability and social initiatives.
• Risks related to intellectual property.
• Risks related to operating in the healthcare industry.
• Risks related to the organizational structure.
• Litigation related risks.
• Ability to accurately forecast revenue and appropriately plan expenses in the future.
• Risks related to general economic factors, natural disasters, or other unexpected events.
• Risks related to fluctuations in tax obligations and effective income tax rate.
• Risks related to healthcare reform legislation and other proposed or future changes impacting the healthcare industry and spending.

Future Outlook

Management anticipates full year 2025 total revenue to increase from 2024, despite an estimated $35 million to $40 million revenue loss due to the Rite Aid bankruptcy and volume reduction in one integrated savings program. Full year Adjusted EBITDA is projected to be between $265 million and $275 million, representing 2% to 6% growth compared to 2024. Q3 revenue is expected to be lower than Q4.

Management Comments

• "I’m excited about the meaningful progress we made during the second quarter delivering against our key initiatives that are designed to better position the Company for sustainable long-term growth." Wendy Barnes, CEO and President
• "We are effectively creating value for core stakeholders—we expanded our integrated access and affordability solutions with pharma, finalized several new deals for pharmacy counter and e-commerce solutions, and announced the launch of our new condition subscription product for erectile dysfunction." Wendy Barnes, CEO and President
• "I am confident in our positive momentum and believe GoodRx is in a strong position to reduce friction in the system and serve as the complement to insurance that helps consumers access and afford the medications they need." Wendy Barnes, CEO and President
• "Overall, GoodRx had a solid financial quarter, continuing to produce growing year-over-year Adjusted EBITDA Margins that underscores the durability of our business model." Chris McGinnis, CFO and Treasurer
• "While we faced some headwinds in the larger healthcare landscape, our total revenue was up 1% versus the prior year, with total revenue of $203.1 million." Chris McGinnis, CFO and Treasurer
• "Pharma manufacturer solutions delivered especially strong results, with 32% year-over-year revenue growth in the second quarter, which has well positioned us to continue performing at similar to even higher levels throughout the rest of 2025." Chris McGinnis, CFO and Treasurer
• "Despite lowering revenue projections, we expect full year Adjusted EBITDA will be in the range of $265 and $275 million, which represents approximately 2% to 6% growth compared to 2024." Chris McGinnis, CFO and Treasurer
• "While lowering revenue expectations due to external factors is disappointing, our core business remains strong and the fact that our Adjusted EBITDA range continues to encompass a portion of our previous range is a testament to our leadership team and the focus on the right strategic initiatives and operating efficiencies." Chris McGinnis, CFO and Treasurer

Industry Context

The company operates within a dynamic U.S. healthcare landscape, facing challenges such as retail pharmacy store closures and shifts in integrated savings programs, which have impacted its prescription transactions revenue and Monthly Active Consumers. However, its strong growth in pharma manufacturer solutions indicates successful adaptation and expansion into new revenue streams within the pharmaceutical industry, leveraging its position to connect consumers, healthcare professionals, and manufacturers.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to assess performance against global benchmarks.

Legal Proceedings

• Legal settlement expenses are mentioned as an adjustment in non-GAAP financial measures, but no specific ongoing legal proceedings are detailed in the filing.

Stakeholder Impact

• Shareholders: Positively impacted by share repurchases and improved profitability, but potentially concerned by declining core business metrics and lowered revenue guidance.
• Consumers: Mixed impact, with a decrease in Monthly Active Consumers and subscription plans, but new offerings like the erectile dysfunction subscription aim to provide more value.
• Pharmacies and Pharmacy Benefit Managers (PBMs): Affected by changes in the retail pharmacy landscape, including store closures (e.g., Rite Aid bankruptcy), and volume reductions in integrated savings programs.
• Pharmaceutical Manufacturers: Positively impacted by the significant growth in pharma manufacturer solutions revenue, indicating increased collaboration and market penetration.

Next Steps

• GoodRx management will host a conference call and webcast on August 7, 2025, to discuss the results and business outlook.
• The company will continue its disciplined approach to capital allocation, focusing on investing for profitable growth, paying down debt, buying back shares, and M&A that aligns with strategic priorities.
• Management expects Q3 revenue to be lower than Q4 for the full year 2025.

Key Dates

Recommendation

The company exhibits a mixed financial performance. While profitability metrics like net income and Adjusted EBITDA show healthy growth, driven by strong performance in pharma manufacturer solutions, the core prescription transactions and subscription segments are facing headwinds, evidenced by declining Monthly Active Consumers and subscription revenue. The lowered full-year revenue guidance due to external factors like the Rite Aid bankruptcy is a concern. However, management's ability to maintain a positive Adjusted EBITDA growth outlook despite these revenue challenges suggests effective cost management and strategic focus. The ongoing share repurchase program is a positive for shareholder value. Given the blend of strategic successes and ongoing challenges in core segments, a 'hold' recommendation is appropriate, awaiting further clarity on the stabilization of the core business and the sustained growth of newer initiatives.

Keywords

GoodRx, GDRX, Prescription Savings, Healthcare Technology, Pharma Manufacturer Solutions, Drug Discounts, Digital Health, Pharmacy Benefit Managers, SEC Filing, Financial Results